Clinical Updates on Relapsed/Refractory Follicular Lymphoma: Where Are We Now and What Is Coming Next?

February 22, 2021
Ian Flinn, MD, PhD, Sarah Cannon Research Institute

,
Caron A. Jacobson, MD, Dana-Farber Cancer Institute

,
Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey

,
Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center

,
Krish Patel, MD, Swedish Cancer Institute

Considerations for using newer treatment options to manage patients with relapsed/refractory follicular lymphoma based on recent clinical trial data, including from the 2020 ASH virtual meeting.



x